Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nevro Corp.
Nevro will lay off 63 people to save at least $14m a year. Most of those savings will be reinvested to cover increases in normal operating costs, merit pay increases and other expenses related to the recent acquisition of Vyrsa.
News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More
Medtech Insight's News We're Watching highlights medtech industry news developments that you may have missed over the last few weeks. Last week, EndoQuest closed a $42m round to support its endoluminal surgery system, Intuitive Ventures closed a $150m round, Noah Surgical announced the first biopsy procedures with its Galaxy technology in Asia, the FDA cleared Smileyscope's VR system to reduce needle anxiety, and Guardant will collaborate with Cancer Research UK.
Nevro is known for its spinal cord stimulation technology but wants to help a wide range of patients with chronic pain, so it is buying Vyrsa, which offers a complete system for sacroiliac joint fusion. In and interview with Medtech Insight, Nevro CEO Kevin Thornal explained how Vyrsa supports Nevro's strategy in this growing market.
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks. Last week, cardiologists got new guidelines for managing patients with atrial fibrillation and Nevro made a big move to expand beyond its core spinal cord stimulation business.
- Implantable Devices
- Other Names / Subsidiaries
- Nevro Medical Limited
- Nevro Medical Pty Ltd.
- Nevro Medical Sarl
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.